AlphaMadera's AlphaVal page classifies Biogen Inc. as a Stable Earnings Power business and values it using P/Adj-EPS × Normalized Multiple, then compares the result to the current market price to flag BIIB as undervalued, fairly valued, or overvalued.

What is Biogen Inc.'s fair value?

Fair value for BIIB comes from a P/Adj-EPS × Normalized Multiple model -- the approach AlphaVal selected for this company's Stable Earnings Power classification. The live AlphaVal page shows bear, base, and bull scenarios alongside the key assumption behind each.

How does AlphaMadera value BIIB?

AlphaVal routes each company to one of ten valuation archetypes based on its business model. BIIB was classified as Stable Earnings Power and is valued using P/Adj-EPS × Normalized Multiple, built from BIIB's most recent reported fundamentals.

BIIB - Biogen Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $247.50 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Mild

Trading 5.9% above fair value

Current Price $225.71

Bear Case $182.62 19.1% downside ($182.62 - $225.71) / $225.71 = -19.1% $15.22 × 12x P/E

Fair Value $213.05 5.6% downside ($213.05 - $225.71) / $225.71 = -5.6% $15.22 × 14x P/E

Bull Case $243.49 7.9% upside ($243.49 - $225.71) / $225.71 = 7.9% $15.22 × 16x P/E

Adjust Assumptions

P/E Multiple

14.0x

Adjusted EPS

15.22$

Key Value Driver

Normalized P/E multiple (14x base case)

Terminal Value % of EV

Implied Market Multiple 14.8x

Market is pricing in (growth)

Plain-Language Summary

Applying a 14x P/E to adjusted EPS of $15.22, the base-case value is $213.05 per share.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (49 analysts) $247.50

Analyst Range $175.00 – $300.00

Divergence from AlphaVal 14%

Warnings

⚠ The company's reported profits differ from official accounting profits by 72%. Check what costs are being left out of the adjusted number.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples